or
Bookmark and Share
Salts of (+)-catechine, their preparation and use, and compositions containing these salts
   
Document Number
US Patent 4285964
Issued Date
August 25, 1981
Link
Inventors
Niebes; Paul (Grez Doiceau,BE)
Roba; Joseph (Ciernont-Houyet,BE)
Map
Abstract
A salt of (+)-catechin formed of the reaction product of (+)-catechin with at least a basic amino-acid, such as L-lysine and L-arginine; a hydrosoluble double salt is formed by the reaction product of (+)-catechin with a basic amino-acid, such as L-lysine and L-arginine, and another inorganic or organic acid.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
13
Comments:
no comments yet
Owner
Continental Pharma (Brussels,BE)
Published
August 25, 1981
Application Number
06/071,076
Filed
August 30, 1979
US Classification
514/457   514/474 514/557 514/564 514/565 514/574 549/316 549/399
Int'l Classification
C07D   311/00   (20060101)   C07D   311/62   (20060101)  
Examiner
Attorney/Law Firm
USPTO Field of Search
260/345.2   424/283  
Related Patents
4507314 - Drug for treating affections provoked by a too high histamine level, of the gastroduodenal mucosa and allergic affections - Owned by Midit, Societe Fiduciaire (Vaduz,LI)

Drug for treating affections provoked by a too high histamine level in the body, for treating affections of the gastroduodenal mucosa and allergic affections, comprising the reaction product of (+)-catechin with at least one basic amino-acid, which is more particularly selected from the group consisting of L-lysine, L-arginine and L-ornithine.

6441178 - Resolution of ritalinic acid salt - Owned by Medeva Europe Limited (GB)

A process for preparing an enantiomerically-enriched form of threo-ritalinic acid, which comprises resolving a mixture of enantiomers of a salt of the acid, said salt being formed with an achiral acid or base, using a chiral resolving agent. The resolved salt can be esterified, to give the therapeutic agent d-threo-methylphenidate.

5702711 - Method for enhancing the rate of skin permeation of lactic acid through use of the L-enantiomer - Owned by Bristol-Myers Squibb Company (New York, NY)

Methods of increasing the rate of lactic acid permeation in skin for the treatment of dermatological disorders by applying a composition containing an inorganic or organic salt of lactic acid in a dermatologically acceptable composition wherein at least 70% of the lactic acid moiety in the salt is L-lactic acid, and compositions for practicing such methods.

5090785 - Multi-compartment container

A compartmentalized container of rectangular-like shape consisting of a lower and upper portion each of which contains at least one compartment for receiving material such as refuse. The upper and lower compartments are accessed by operation of pedals operating on the top lid of the container and the lower front panel of the container respectively. This allows hands-free use of all the compartments for segregating refuse into reusable or recyclable components, such as bottles, papers, or cans. The container is designed to use surplus grocery and shopping bags in addition to normal garbage bags in the containment and disposal process.

4857320 - Method of enhancing the solubility of tissue plasminogen activator - Owned by Monsanto Company (St. Louis, MO)

The solubility of tissue plasminogen activator in aqueous solution is enhanced by incorporating therein arginine or a non-toxic salt of arginine in an amount effective to increase the solubility of the t-PA without substantially inhibiting its potential biological activity upon administration.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us